Prostate Cancer Clinical Trial

Clinical Trial Finder Prostate Cancer Trials

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

See Locations Near You

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone and in combination with nivolumab in participants with advanced tumors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent malignant tumor. Eligible tumor types are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction, castration-resistant prostate cancer (CRPC), ovarian, squamous cell carcinoma of the head and neck (SCCHN), bladder, melanoma, mesothelioma, triple negative breast cancer (TNBC), and soft tissue sarcoma, except for participants with tumors with central nervous system (CNS) metastases as the only site of active disease
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Prostate Cancer Working Group 3 (PCWG3) (for prostate cancer), or modified Response Evaluation Criteria in Solid tumors (mRECIST) (for mesothelioma)
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Adequate organ function

Exclusion Criteria:

Prior organ or tissue allograft
Leptomeningeal metastases
Untreated CNS metastases
Serious or uncontrolled medical disorders

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

112

Study ID:

NCT05298592

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Local Institution
Los Angeles California, 90025, United States More Info
Site 0004
Contact
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Martin Gutierrez, Site 0001
Contact
551-996-5863
Carolina Biooncology Institute, Pllc
Huntersville North Carolina, 28078, United States More Info
John Powderly, Site 0002
Contact
704-654-0485
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
Sanford Cancer Center
Sioux Falls South Dakota, 57104, United States More Info
Steven Powell, Site 0013
Contact
605-328-8000
Mary Crowley Cancer Research
Dallas Texas, 75230, United States More Info
Minal Barve, Site 0005
Contact
972-566-3000
Local Institution
Richmond Virginia, 23298, United States More Info
Site 0006
Contact
Local Institution - 0012
Brussels MO, 1200, Belgium More Info
Site 0012
Contact
Local Institution
Barcelona , 08916, Spain More Info
Site 0007
Contact
Local Institution - 0009
Madrid , 28041, Spain More Info
Site 0009
Contact
Local Institution
Malaga , 29010, Spain More Info
Site 0008
Contact
Load More

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

112

Study ID:

NCT05298592

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider